Clinical trials: HBOC Syndrome
Hereditary Breast and Ovarian Cancer Syndrome
Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk
Young female counselees (18-40 years) belonging to HBOC families with a known mutation on BRCA-genes or not, receive a lot of information regarding their cancer risk. Information sources are numerous and sometimes contradictory.
- Trial name
- NCT02705924
- Testing
- psychoeducation
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Centre Jean Perrin
Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation
Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations
This phase II trial studies how well surgery works in preventing ovarian cancer in patients with genetic mutations at risk of ovarian cancer.
- Conditions
- Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Deleterious BRIP1 Gene Mutation
- Trial name
- NCT02760849
- Testing
- Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment
- Where
- 9 sites in United States
- Volunteers
- 374 people
- Sponsor
- M.D. Anderson Cancer Center
HBOC Syndrome, DNA Damage
Nutritional Intervention and DNA Damage of Patients With HBOC
Breast and Ovarian Cancer Syndrome (HBOC) is characterized by mutations in tumor suppressor genes such as BRCA1 and BRCA2, which increase the carrier's risk of developing breast and ovarian cancer, especially before 40.
- Conditions
- HBOC Syndrome, DNA Damage, Nutrition Therapy
- Trial name
- NCT05306002
- Testing
- Antioxidant therapy
- Where
- Mexico
- Volunteers
- 34 people
- Sponsor
- Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome
Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
This research trial collects information about types of treatment and the cost of these procedures in women with elevated genetic risk for ovarian cancer who participated on the Gynecology Oncology Group (GOG)-0199 trial.
- Conditions
- Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT01445275
- Testing
- Evaluation of Cancer Risk Factors, Medical Chart Review, Study of Socioeconomic and Demographic Variables
- Where
- United States
- Sponsor
- Gynecologic Oncology Group
Hereditary Breast and Ovarian Cancer Syndrome
Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
Breast cancer (BC) is a major health problem and the most prevalent cancer among women.In a substantial proportion of familial cases, germ-line mutations in either BRCA1/2 can be detected.
- Trial name
- NCT01367639
- Testing
- Inquiry Based Stress Reduction (IBSR) program
- Where
- Israel
- Volunteers
- 67 people
- Sponsor
- Sheba Medical Center
Breast Cancer, Ovarian Cancer
EHR Intervention to Increase HBOC Genetic Testing
The purpose of this research study is to test how well a new approach - using tools built into the electronic health record (EHR)- can help increase genetic testing for hereditary breast and ovarian cancer (HBOC) in women who…
- Conditions
- Breast Cancer, Ovarian Cancer, Hereditary Cancer Syndrome
- Trial name
- ELISABETH (NCT07876349)
- Testing
- ELISABETH Evidence-Informed Program (EIP)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Columbia University
Hereditary Breast and Ovarian Cancer Syndrome
Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer
The purpose of this study is to determine proportion of patients presented a search allelic imbalance of expression of genes BRCA 1 and 2 in population with hereditary breast and/or ovarian cancer risk and negative for deletion…
- Trial name
- EXSAL (NCT01333748)
- Testing
- blood collection
- Where
- 6 sites in France
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- Centre Francois Baclesse
BRCA1 Mutation, BRCA2 Mutation
Radical Fimbriectomy for Young BRCA Mutation Carriers
Some BRCA-mutated women are reluctant to undergo laparoscopic bilateral salpingo-oophorectomy. The goal of the bilateral laparoscopic radical fimbriectomy the investigators suggest, is to suppress the tubal source of possible…
- Conditions
- BRCA1 Mutation, BRCA2 Mutation, Hereditary Breast and Ovarian Cancer
- Trial name
- FIMBRIECTOMIE (NCT01608074)
- Testing
- Radical fimbriectomy, Histopathology SEE-FIM
- Where
- 14 sites in France
- Volunteers
- 123 people
- Sponsor
- Centre Oscar Lambret
Hereditary Cancer Syndromes, BRCA1 Hereditary Breast and Ovarian Cancer Syndrome
Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment
This study aims to improve cancer prevention and surveillance adherence in patients with Hereditary Cancer Syndromes (HCS), particularly those living in rural areas.
- Conditions
- Hereditary Cancer Syndromes, BRCA1 Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
- Trial name
- LINC (NCT07381985)
- Testing
- Longitudinal Cancer Genetics Follow-Up Program
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Vermont Medical Center
Cancer
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies.
- Trial name
- NCT02253251
- Testing
- KRAS-variant and microRNA binding site mutation testing
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- MiraKind
Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00253539
- Testing
- arzoxifene hydrochloride, tamoxifen citrate
- Volunteers
- 3 people
- Sponsor
- The Cleveland Clinic
Hereditary Breast and Ovarian Cancer
Study of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT)
1. Premenopausal BRCA1 / 2 or PALB2 gene mutation carriers who receive hormone replacement therapy (HRT) after preventive salpingo-oophorectomy (PBSO) have a better quality of sexual, psychological, cardiovascular and bone health…
- Trial name
- BRCA-HRT (NCT05409222)
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Genetic Predisposition to Disease, Breast Cancer Female
Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
The goal of this sequential study design is to increase genetic testing in those meeting national clinical guidelines. The main question it aims to answer is: which intervention is most effective in uptake of genetic testing for…
- Conditions
- Genetic Predisposition to Disease, Breast Cancer Female, Ovarian Cancer, Hereditary Breast and Ovarian Cancer
- Trial name
- NCT05721326
- Testing
- Sequential EHR Communications
- Where
- United States
- Volunteers
- 1,283 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Ovarian Neoplasm, Cancer Genetics
Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans
Background: Certain genetic mutations are linked to higher rates of cancer. It is important for people with these mutations to tell their families about it.
- Conditions
- Ovarian Neoplasm, Cancer Genetics, Breast Cancer
- Trial name
- NCT01374685
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
Identification of BRCA mutations in ovarian cancer patients may help guide cancer therapies, prognosis, post-operative screening, and other preventative treatments beyond the initial diagnosis.
- Conditions
- BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation, MSH2 A636P, MLH1 Gene Mutation
- Trial name
- NCT04009148
- Testing
- CASCADE genetic screening
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Breast Cancer, Hereditary Breast and Ovarian Cancer Syndrome
Tissue Expansion in Breast Reconstruction Without Drains
The primary objective of this small feasibility pilot study is to demonstrate that implant-based breast reconstruction (after treatment for cancer) can successfully be performed without prolonged drain placement, using a tissue…
- Conditions
- Breast Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Breast Implant; Complications
- Trial name
- NCT03784859
- Testing
- Insertion of Tissue Expander with Fluid Reservoir
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Cedars-Sinai Medical Center
Acute Leukemia, Adenomatous Polyposis
Familial Investigations of Childhood Cancer Predisposition
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll.
- Conditions
- Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML
- Trial name
- SJFAMILY (NCT03050268)
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- St. Jude Children's Research Hospital
Hereditary Breast/Ovarian Cancer (brca1, brca2), Lynch Syndrome
Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes
The goal of this clinical trial is to address care gaps for participants at high risk of breast and ovarian cancer (HBOC), or Lynch syndrome (LS) because of testing positive for specific genetic variants.
- Conditions
- Hereditary Breast/Ovarian Cancer (brca1, brca2), Lynch Syndrome, Genetic Variation, HBOC Syndrome
- Trial name
- PC-CDS (NCT06914726)
- Testing
- Patient Centered Clinical Decision Support (PC-CDS)
- Where
- United States
- Volunteers
- 2,488 people
- Sponsor
- HealthPartners Institute
Breast Cancer, Ovarian Cancer
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Background: Carboplatin is approved by the Food and Drug Administration to treat cancer. AZD2281 is an experimental drug in a class of agents called PARP inhibitors.
- Trial name
- NCT01445418
- Testing
- AZ2281 + Carboplatin
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Hereditary Cancer Syndrome
CfDNA in Hereditary And High-risk Malignancies 2
The goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes.
- Trial name
- CHARM2 (NCT06726642)
- Testing
- Cell-free DNA analysis
- Where
- 8 sites in Canada
- Volunteers
- 1,000 people
- Sponsor
- University Health Network, Toronto